{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:02:08Z","timestamp":1792854128662,"version":"4.5.0"},"reference-count":309,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/MED-FSL\/31719\/2017"],"award-info":[{"award-number":["PTDC\/MED-FSL\/31719\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/00051\/2020"],"award-info":[{"award-number":["UIDB\/00051\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDP\/00051\/2020"],"award-info":[{"award-number":["UIDP\/00051\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Pulmonary arterial hypertension (PAH), also known as Group 1 Pulmonary Hypertension (PH), is a PH subset characterized by pulmonary vascular remodeling and pulmonary arterial obstruction. PAH has an estimated incidence of 15\u201350 people per million in the United States and Europe, and is associated with high mortality and morbidity, with patients' survival time after diagnosis being only 2.8 years. According to current guidelines, right heart catheterization is the gold standard for diagnostic and prognostic evaluation of PAH patients. However, this technique is highly invasive, so it is not used in routine clinical practice or patient follow-up. Thereby, it is essential to find new non-invasive strategies for evaluating disease progression. Biomarkers can be an effective solution for determining PAH patient prognosis and response to therapy, and aiding in diagnostic efforts, so long as their detection is non-invasive, easy, and objective. This review aims to clarify and describe some of the potential new candidates as circulating biomarkers of PAH.<\/jats:p>","DOI":"10.3389\/fcvm.2022.924873","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T07:31:58Z","timestamp":1657783918000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["An Overview of Circulating Pulmonary Arterial Hypertension Biomarkers"],"prefix":"10.3389","volume":"9","author":[{"given":"Joana","family":"Santos-Gomes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00eas","family":"Gandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Ad\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Perros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Br\u00e1s-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.acvd.2016.03.004","article-title":"Pulmonary arterial hypertension: Basic knowledge for clinicians","volume":"109","author":"Santos-Ribeiro","year":"2016","journal-title":"Arch Cardiovasc Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1A","DOI":"10.1016\/j.amjcard.2012.12.002","article-title":"Pulmonary arterial hypertension: New insights into the optimal role of current and emerging prostacyclin therapies","volume":"111","author":"Waxman","year":"2013","journal-title":"Am J Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"200009","DOI":"10.1183\/16000617.0009-2020","article-title":"BNP\/NT-proBNP in pulmonary arterial hypertension: time for point-of-care testing?","volume":"29","author":"Lewis","year":"2020","journal-title":"Eur Respirat Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.21542\/gcsp.2017.14","article-title":"Nitric oxide and pulmonary arterial hypertension","volume":"58","author":"Chester","year":"2017","journal-title":"Glob Cardiol Sci Pract."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur Respir J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"106099","DOI":"10.1016\/j.rmed.2020.106099","article-title":"Evaluation and management of pulmonary arterial hypertension","volume":"171","author":"Beshay","year":"2020","journal-title":"Respirat Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.5339\/gcsp.2014.29","article-title":"The role of endothelin-1 in pulmonary arterial hypertension","volume":"2014","author":"Chester","year":"2014","journal-title":"Glob Cardiol Sci Practice."},{"key":"B8","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nrcardio.2017.84","article-title":"Epidemiology and treatment of pulmonary arterial hypertension","volume":"14","author":"Lau","year":"2017","journal-title":"Nat Rev Cardiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1093\/cvr\/cvy076","article-title":"Urocortin-2 improves right ventricular function and attenuates pulmonary arterial hypertension","volume":"114","author":"Ad\u00e3o","year":"2018","journal-title":"Cardiovasc Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/j.1440-1843.2006.00778.x","article-title":"Pulmonary arterial hypertension: new insights and new hope","volume":"11","author":"Martin","year":"2006","journal-title":"Respirology."},{"key":"B11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12890-015-0045-8","article-title":"Oxidative stress and nitric oxide signaling related biomarkers in patients with pulmonary hypertension: a case control study","volume":"15","author":"Zhang","year":"2015","journal-title":"BMC Pulmonary Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.healun.2014.12.005","article-title":"Circulating biomarkers in pulmonary arterial hypertension: Update and future direction","volume":"34","author":"Pezzuto","year":"2015","journal-title":"J Heart Lung Transplant."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1161\/CIRCULATIONAHA.114.008750","article-title":"Endothelial-to-mesenchymal transition in pulmonary hypertension","volume":"131","author":"Ranchoux","year":"2015","journal-title":"Circulation."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1161\/HYPERTENSIONAHA.115.06370","article-title":"Leukotriene B4 activates pulmonary artery adventitial fibroblasts in pulmonary hypertension","volume":"66","author":"Qian","year":"2015","journal-title":"Hypertension."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22041756","article-title":"Central role of dendritic cells in pulmonary arterial hypertension in human and mice","volume":"22","author":"van Uden","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1183\/16000617.0161-2021","article-title":"Smouldering fire or conflagration? An illustrated update on the concept of inflammation in pulmonary arterial hypertension","volume":"30","author":"Perros","year":"2021","journal-title":"Eur Respir Rev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1183\/13993003.01177-2015","article-title":"The 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: a practical chronicle of progress","volume":"46","author":"Lau","year":"2015","journal-title":"Eur Respirat J."},{"key":"B18","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/path.4833","article-title":"The role of genetics in pulmonary arterial hypertension","volume":"241","author":"Ma","year":"2017","journal-title":"J Pathol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"13S","DOI":"10.1016\/j.jacc.2004.02.029","article-title":"Cellular and molecular pathobiology of pulmonary arterial hypertension","volume":"43","author":"Humbert","year":"2004","journal-title":"J Am Coll Cardiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"216","DOI":"10.7326\/0003-4819-107-2-216","article-title":"Primary pulmonary hypertension. A national prospective study","volume":"107","author":"Rich","year":"1987","journal-title":"Ann Intern Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ccl.2016.04.001","article-title":"World Health Organization group I pulmonary hypertension","volume":"34","author":"Prins","year":"2016","journal-title":"Cardiol Clinics."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1164\/rccm.200510-1668OC","article-title":"Pulmonary arterial hypertension in France: results from a national registry","volume":"173","author":"Humbert","year":"2006","journal-title":"Am J Respir Crit Care Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12931-016-0396-6","article-title":"Novel biomarkers for pulmonary arterial hypertension","volume":"17","author":"Anwar","year":"2016","journal-title":"Respiratory Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework","volume":"69","author":"Atkinson","year":"2001","journal-title":"Clin Pharmacol Therap."},{"key":"B25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000488245","article-title":"C-proSP-B: A possible biomarker for pulmonary diseases?","volume":"96","author":"Kahn","year":"2018","journal-title":"Respiration."},{"key":"B26","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1183\/09031936.00160307","article-title":"Biomarkers in pulmonary hypertension","volume":"32","author":"Warwick","year":"2008","journal-title":"Eur Respir J."},{"key":"B27","doi-asserted-by":"publisher","first-page":"345","DOI":"10.4103\/2230-8210.86978","article-title":"Natriuretic peptides: Diagnostic and therapeutic use","volume":"15","author":"Pandit","year":"2011","journal-title":"Ind J Endocrinol Metab."},{"key":"B28","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1177\/147323000503300509","article-title":"The significance of elevated brain natriuretic peptide levels in chronic obstructive pulmonary disease","volume":"33","author":"Bozkanat","year":"2005","journal-title":"J Int Med Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/S0003-4975(02)03654-8","article-title":"Plasma brain natriuretic peptide as a noninvasive marker for efficacy of pulmonary thromboendarterectomy","volume":"74","author":"Nagaya","year":"2002","journal-title":"Ann Thoracic Surg."},{"key":"B30","first-page":"43","article-title":"Biochemical markers in the management of pulmonary hypertension","volume":"135","author":"Aubert","year":"2005","journal-title":"Swiss Med Weekly."},{"key":"B31","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/S0140-6736(03)13976-1","article-title":"B-type natriuretic peptide in cardiovascular disease","volume":"362","author":"De Lemos","year":"2003","journal-title":"Lancet."},{"key":"B32","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1161\/01.CIR.102.8.865","article-title":"Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension","volume":"102","author":"Nagaya","year":"2000","journal-title":"Circulation."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1164\/rccm.200410-1411OC","article-title":"Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study","volume":"171","author":"Wilkins","year":"2005","journal-title":"Am J Respiratory Crit Care Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1053\/hj.1998.v136.89729","article-title":"Secretion patterns of brain natriuretic peptide and atrial natriuretic peptide in patients with or without pulmonary hypertension complicating atrial septal defect","volume":"136","author":"Nagaya","year":"1998","journal-title":"Am Heart J."},{"key":"B35","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1164\/rccm.200308-1142OC","article-title":"Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension","volume":"170","author":"Leuchte","year":"2004","journal-title":"Am J Respir Crit Care Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1161\/01.CIR.0000074039.45523.BE","article-title":"Prognostic role of brain natriuretic peptide in acute pulmonary embolism","volume":"107","author":"Kucher","year":"2003","journal-title":"Circulation."},{"key":"B37","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.jacc.2003.09.051","article-title":"Clinical significance of brain natriuretic peptide in primary pulmonary hypertension","volume":"43","author":"Leuchte","year":"2004","journal-title":"J Am Coll Cardiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/S0735-1097(97)00452-X","article-title":"Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension","volume":"31","author":"Nagaya","year":"1998","journal-title":"J Am Coll Cardiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1002\/art.11345","article-title":"N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers","volume":"48","author":"Allanore","year":"2003","journal-title":"Arthritis Rheumatism."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/S0735-1097(01)01490-5","article-title":"Atrial natriuretic peptide in severe primary and nonprimary pulmonary hypertension: Response to iloprost inhalation","volume":"38","author":"Wiedemann","year":"2001","journal-title":"J Am Coll Cardiol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/0024-3205(86)90137-2","article-title":"Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man","volume":"38","author":"Yandle","year":"1986","journal-title":"Life Sci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/BF00870995","article-title":"The pharmacokinetics of alpha-human atrial natriuretic polypeptide in healthy subjects","volume":"31","author":"Nakao","year":"1986","journal-title":"Eur J Clin Pharmacol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1210\/jcem.76.1.8380606","article-title":"Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man","volume":"76","author":"Holmes","year":"1993","journal-title":"J Clin Endocrinol Metab."},{"key":"B44","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1161\/01.CIR.0000084544.54513.E2","article-title":"Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension","volume":"108","author":"Torbicki","year":"2003","journal-title":"Circulation."},{"key":"B45","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1183\/09031936.00067011","article-title":"Sensitive cardiac troponin I predicts poor outcomes in pulmonary arterial hypertension","volume":"39","author":"Heresi","year":"2012","journal-title":"Eur Respir J."},{"key":"B46","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1042\/CS20100014","article-title":"High-sensitive troponin T: A novel biomarker for prognosis and disease severity in patients with pulmonary arterial hypertension","volume":"119","author":"Filusch","year":"2010","journal-title":"Clin Sci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1016\/j.amjcard.2013.02.036","article-title":"Association of cardiac troponin i with disease severity and outcomes in patients with pulmonary hypertension","volume":"111","author":"V\u00e9lez-Mart\u00ednez","year":"2013","journal-title":"Am J Cardiol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1373\/clinchem.2009.128397","article-title":"Cystatin C and cardiovascular risk","volume":"55","author":"Taglieri","year":"2009","journal-title":"Clin Chem."},{"key":"B49","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S1885-5857(10)70090-6","article-title":"Cystatin C and cardiovascular risk in the general population","volume":"63","author":"Cepeda","year":"2010","journal-title":"Rev Espa\u00f1ola Cardiol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1053\/ajkd.2000.8237","article-title":"Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment","volume":"36","author":"Coll","year":"2000","journal-title":"Am J Kidney Dis."},{"key":"B51","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/0014-5793(88)80276-X","article-title":"Efficient production of native, biologically active human cystatin C by Escherichia coli","volume":"236","author":"Abrahamson","year":"1988","journal-title":"FEBS Lett."},{"key":"B52","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/resp.12259","article-title":"Cystatin C: A potential biomarker for pulmonary arterial hypertension","volume":"19","author":"Fenster","year":"2014","journal-title":"Respirology."},{"key":"B53","volume-title":"20 - Cardiovascular Disease","author":"Ard","year":"2006"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1161\/hc4601.098514","article-title":"Homocysteine impairs the nitric oxide synthase pathway","volume":"104","author":"St\u00fchlinger","year":"2001","journal-title":"Circulation."},{"key":"B55","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0954-6111(03)00038-6","article-title":"Association between hyperhomocysteinemia and primary pulmonary hypertension","volume":"97","author":"Arroliga","year":"2003","journal-title":"Respir Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s00246-012-0321-9","article-title":"Elevated homocysteine and asymmetric dimethyl arginine levels in pulmonary hypertension associated with congenital heart disease","volume":"33","author":"Sanli","year":"2012","journal-title":"Pediatric Cardiol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"4981982","DOI":"10.1155\/2019\/4981982","article-title":"Red cell distribution width and platelet count as biomarkers of pulmonary arterial hypertension in patients with connective tissue disorders","volume":"2019","author":"Bellan","year":"2019","journal-title":"Dis Markers."},{"key":"B58","doi-asserted-by":"publisher","first-page":"e19089","DOI":"10.1097\/MD.0000000000019089","article-title":"Prognostic impact of red blood cell distribution width in pulmonary hypertension patients","volume":"99","author":"Liu","year":"2020","journal-title":"Medicine."},{"key":"B59","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.amjcard.2009.05.016","article-title":"Usefulness of red cell distribution width as a prognostic marker in pulmonary hypertension","volume":"104","author":"Hampole","year":"2009","journal-title":"Am J Cardiol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12935-018-0558-3","article-title":"Prognostic role of RDW in hematological malignancies: A systematic review and meta-analysis","volume":"18","author":"Ai","year":"2018","journal-title":"Cancer Cell Int."},{"key":"B61","doi-asserted-by":"publisher","first-page":"121","DOI":"10.4021\/jocmr1214w","article-title":"Is red cell distribution width a novel biomarker of breast cancer activity? Data from a pilot study","volume":"5","author":"Seretis","year":"2013","journal-title":"J Clin Med Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.hlc.2017.08.007","article-title":"Red blood cells distribution width as a potential prognostic biomarker in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension","volume":"27","author":"Smukowska-Gorynia","year":"2018","journal-title":"Heart Lung Circulation."},{"key":"B63","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/0736-4679(91)90592-4","article-title":"The red blood cell distribution width","volume":"9","author":"Evans","year":"1991","journal-title":"J Emerg Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"e3853454","DOI":"10.1155\/2019\/3853454","article-title":"Red blood cell distribution width predicts pulmonary hypertension secondary to chronic obstructive pulmonary disease","volume":"2019","author":"Yang","year":"2019","journal-title":"Canad Respir J."},{"key":"B65","doi-asserted-by":"publisher","first-page":"e20477","DOI":"10.3390\/cells10020477","article-title":"Iron deficiency in pulmonary arterial hypertension: a deep dive into the mechanisms","volume":"10","author":"Quatredeniers","year":"2021","journal-title":"Cells."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/20458940211021301","article-title":"Iron deficiency in pulmonary arterial hypertension: perspectives","volume":"11","author":"Quatredeniers","year":"2021","journal-title":"Pulmonary Circulation."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1183\/13993003.01486-2019","article-title":"Mendelian randomisation analysis of red cell distribution width in pulmonary arterial hypertension","volume":"55","author":"Ulrich","year":"2020","journal-title":"Eur Respir J."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1136\/hrt.2011.224857","article-title":"Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension","volume":"97","author":"Rhodes","year":"2011","journal-title":"Heart."},{"key":"B69","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.pharmthera.2005.11.001","article-title":"Cardiovascular endothelins: Essential regulators of cardiovascular homeostasis","volume":"111","author":"Brunner","year":"2006","journal-title":"Pharmacol Therap."},{"key":"B70","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1161\/01.CIR.102.19.2434","article-title":"Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs","volume":"102","author":"L\u00fcscher","year":"2000","journal-title":"Circulation."},{"key":"B71","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00018-010-0518-0","article-title":"Endothelin","volume":"68","author":"Kawanabe","year":"2011","journal-title":"Cell Mol Life Sci."},{"key":"B72","doi-asserted-by":"publisher","first-page":"464","DOI":"10.7326\/0003-4819-114-6-464","article-title":"Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease?","volume":"114","author":"Stewart","year":"1991","journal-title":"Ann Internal Med."},{"key":"B73","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1056\/NEJM199312303292706","article-title":"The L-arginine-nitric oxide pathway","volume":"329","author":"Epstein","year":"1993","journal-title":"New Engl J Med."},{"key":"B74","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1097\/00005344-199506263-00018","article-title":"Cytokine regulation of endothelin-1 release from bovine aortic endothelial cells","volume":"26","author":"Roger","year":"1995","journal-title":"J Cardiovasc Pharmacol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.cgh.2021.04.028","article-title":"A prospective diet-wide association study for risk of colorectal cancer in EPIC","volume":"20","author":"Papadimitriou","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study","volume":"358","author":"Channick","year":"2001","journal-title":"Lancet."},{"key":"B77","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1164\/rccm.200307-957OC","article-title":"Sitaxsentan therapy for pulmonary arterial hypertension","volume":"169","author":"Barst","year":"2004","journal-title":"Am J Respir Crit Care Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","volume":"117","author":"Gali\u00e8","year":"2008","journal-title":"Circulation."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1016\/j.jacc.2009.07.033","article-title":"Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension","volume":"54","author":"Oudiz","year":"2009","journal-title":"J Am Coll Cardiol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.healun.2018.11.006","article-title":"Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension\u2013related hospitalization in the AMBITION trial","volume":"38","author":"Vachi\u00e9ry","year":"2019","journal-title":"J Heart Lung Transplant."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1093\/eurheartj\/ehx123","article-title":"Randomized controlled trials: a solid platform for observational research","volume":"38","author":"Leary","year":"2017","journal-title":"Eur Heart J."},{"key":"B82","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ejim.2007.04.002","article-title":"Endothelins in health and disease","volume":"18","author":"Shah","year":"2007","journal-title":"Eur J Internal Med."},{"key":"B83","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/j.peptides.2004.07.007","article-title":"Adrenomedullin in the treatment of pulmonary hypertension","volume":"25","author":"Nagaya","year":"2004","journal-title":"Peptides (NY)."},{"key":"B84","first-page":"13428","article-title":"An abundant and specific binding site for the novel vasodilator adrenomedullin in the rat","volume":"28","author":"Owji","year":"1995","journal-title":"Nat Commun."},{"key":"B85","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/ejhf.1366","article-title":"Adrenomedullin in heart failure: pathophysiology and therapeutic application","volume":"21","author":"Voors","year":"2019","journal-title":"Eur J Heart Fail."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1177\/2045894020931317","article-title":"Plasma adrenomedullin peptides and precursor levels in pulmonary arterial hypertension disease severity and risk stratification","volume":"10","author":"Bouzina","year":"2020","journal-title":"Pulmonary Circul."},{"key":"B87","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.tem.2007.11.001","article-title":"Copeptin: clinical use of a new biomarker","volume":"19","author":"Morgenthaler","year":"2008","journal-title":"Trends Endocrinol Metab."},{"key":"B88","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/1465-9921-14-130","article-title":"Circulating levels of copeptin predict outcome in patients with pulmonary arterial hypertension","volume":"14","author":"Nickel","year":"2013","journal-title":"Respiratory Res."},{"key":"B89","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1172\/JCI107423","article-title":"Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma","volume":"52","author":"Robertson","year":"1973","journal-title":"J Clin Investig."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.healun.2013.06.020","article-title":"An exploratory panel of biomarkers for risk prediction in pulmonary hypertension: Emerging role of ct-proet-1","volume":"32","author":"Silva Marques","year":"2013","journal-title":"J Heart Lung Transplant."},{"key":"B91","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1136\/ard.55.1.7","article-title":"Nitric oxide","volume":"55","author":"Farrell","year":"1996","journal-title":"Ann Rheum Dis."},{"key":"B92","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/HJH.0b013e328332bcdb","article-title":"Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension","volume":"28","author":"Crosswhite","year":"2010","journal-title":"J Hyperten."},{"key":"B93","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.freeradbiomed.2005.08.047","article-title":"Nitric oxide as a cellular antioxidant: A little goes a long way","volume":"40","author":"Hummel","year":"2006","journal-title":"Free Rad Biol Med."},{"key":"B94","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1164\/rccm.200412-1684OC","article-title":"Decreased exhaled nitric oxide in pulmonary arterial hypertension: Response to Bosentan therapy","volume":"172","author":"Girgis","year":"2005","journal-title":"Am J Respir Crit Care Med."},{"key":"B95","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1164\/ajrccm.158.3.9802066","article-title":"Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension","volume":"158","author":"Kaneko","year":"1998","journal-title":"Am J Respir Crit Care Med."},{"key":"B96","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s004080000064","article-title":"High levels of nitric oxide in individuals with pulmonary hypertension receiving epoprostenol therapy","volume":"179","author":"\u00d6zkan","year":"2001","journal-title":"Lung."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1164\/ajrccm.158.4.9802113","article-title":"Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension","volume":"158","author":"Archer","year":"1998","journal-title":"Am J Respir Crit Care Med."},{"key":"B98","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1042\/CS19990006","article-title":"Effect of nebulized epoprostenol (prostacyclin) on exhaled nitric oxide in patients with pulmonary hypertension due to congenital heart disease and in normal controls","volume":"97","author":"Forrest","year":"1999","journal-title":"Clin Sci."},{"key":"B99","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1378\/chest.111.1.44","article-title":"Exhaled nitric oxide during exercise in primary pulmonary hypertension and pulmonary fibrosis","volume":"111","author":"Riley","year":"1997","journal-title":"Chest."},{"key":"B100","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1164\/rccm.200406-710ST","article-title":"ATS\/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005","volume":"171","author":"American Thoracic","year":"2005","journal-title":"Am J Respir Crit Care Med."},{"key":"B101","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s001340000774","article-title":"Inhibition of lung phosphodiesterase improves responsiveness to inhaled nitric oxide in isolated-perfused lungs from rats challenged with endotoxin","volume":"27","author":"Holzmann","year":"2001","journal-title":"Intensive Care Med."},{"key":"B102","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1056\/NEJM199507273330403","article-title":"Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension","volume":"333","author":"Giaid","year":"1995","journal-title":"N Engl J Med."},{"key":"B103","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/(SICI)1096-9896(199807)185:3&lt;313::AID-PATH93&gt;3.0.CO;2-8","article-title":"High expression of endothelial nitric oxide synthase in plexiform lesions of pulmonary hypertension","volume":"185","author":"Mason","year":"1998","journal-title":"J Pathol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/1358836X0501000103","article-title":"ADMA: Its role in vascular disease","volume":"10","author":"Cooke","year":"2005","journal-title":"Vasc Med."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1161\/01.ATV.0000168414.06853.f0","article-title":"Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension","volume":"25","author":"Kielstein","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.ijcard.2014.04.156","article-title":"Blood biomarkers and their potential role in pulmonary arterial hypertension associated with congenital heart disease. A systematic review","volume":"174","author":"Giannakoulas","year":"2014","journal-title":"Int J Cardiol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/00005344-200104000-00016","article-title":"Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension","volume":"37","author":"Gorenflo","year":"2001","journal-title":"J Cardiovasc Pharmacol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1164\/rccm.200702-278OC","article-title":"Asymmetric dimethylarginine is increased in chronic thromboembolic pulmonary hypertension","volume":"176","author":"Skoro-Sajer","year":"2007","journal-title":"Am J Respir Crit Care Med."},{"key":"B109","doi-asserted-by":"publisher","first-page":"9265","DOI":"10.1073\/pnas.84.24.9265","article-title":"Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide","volume":"84","author":"Ignarro","year":"1987","journal-title":"Proc Natl Acad Sci USA."},{"key":"B110","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1183\/09031936.01.00075501","article-title":"Discrepant distribution of big endothelin (ET)-1 and ET receptors in the pulmonary artery","volume":"18","author":"Takahashi","year":"2001","journal-title":"Eur Respir J."},{"key":"B111","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1183\/09031936.02.00982001","article-title":"Lung cGMP release subsequent to NO inhalation in pulmonary hypertension: responders versus nonresponders","volume":"19","author":"Ghofrani","year":"2002","journal-title":"Eur Resp J."},{"key":"B112","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1203\/00006450-199802000-00002","article-title":"Cyclic-GMP-Binding, Cyclic-GMP-Specific phosphodiesterase (PDE5) gene expression is regulated during rat pulmonary development","volume":"43","author":"Sanchez","year":"1998","journal-title":"Pediatric Res."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1136\/thx.53.12.1059","article-title":"Urinary cGMP concentrations in severe primary pulmonary hypertension","volume":"53","author":"Bogdan","year":"1998","journal-title":"Thorax."},{"key":"B114","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.bbrc.2005.06.183","article-title":"High lung PDE5: A strong basis for treating pulmonary hypertension with PDE5 inhibitors","volume":"334","author":"Corbin","year":"2005","journal-title":"Biochem Biophys Res Commun."},{"key":"B115","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Gali\u00e8","year":"2009","journal-title":"Circulation."},{"key":"B116","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1161\/01.CIR.0000074226.20466.B1","article-title":"Phosphodiesterase Type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension","volume":"107","author":"Sebkhi","year":"2003","journal-title":"Circulation."},{"key":"B117","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1161\/01.CIR.0000016641.12984.DC","article-title":"Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension","volume":"105","author":"Michelakis","year":"2002","journal-title":"Circulation."},{"key":"B118","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/ehjcvp\/pvv039","article-title":"The current role and future prospects of D-dimer biomarker","volume":"2","author":"Soomro","year":"2016","journal-title":"Eur Heart J."},{"key":"B119","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.hfc.2020.03.004","article-title":"Pulmonary embolism: a practical guide for the busy clinician","volume":"16","author":"Demelo-Rodriguez","year":"2020","journal-title":"Heart Fail Clin."},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2010.08.020","article-title":"Calibrated automated thrombography demonstrates hypercoagulability in patients with idiopathic pulmonary arterial hypertension","author":"Tournier","year":"2010","journal-title":"Thrombosis Res."},{"key":"B121","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1378\/chest.122.5.1674","article-title":"Significance of a plasma D-dimer test in patients with primary pulmonary hypertension","volume":"122","author":"Shitrit","year":"2002","journal-title":"Chest."},{"key":"B122","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1159\/000063270","article-title":"Elevation of ELISA D-dimer levels in patients with primary pulmonary hypertension","volume":"69","author":"Shitrit","year":"2002","journal-title":"Respiration."},{"key":"B123","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1097\/MBC.0000000000000523","article-title":"Platelet abnormalities in adults with severe pulmonary arterial hypertension related to congenital heart defects (Eisenmenger syndrome)","volume":"27","author":"Remkov\u00e1","year":"2016","journal-title":"Blood Coagul Fibrinolysis."},{"key":"B124","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1477-9560-4-2","article-title":"Plasma D-dimer concentration in patients with systemic sclerosis","volume":"4","author":"Lippi","year":"2006","journal-title":"Thrombosis J."},{"key":"B125","first-page":"2024","article-title":"D-dimer and pulmonary arterial hypertension in systemic sclerosis","volume":"90","author":"Kiatchoosakun","year":"2007","journal-title":"J Med Assoc Thai."},{"key":"B126","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1161\/01.CIR.100.8.869","article-title":"Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates","volume":"100","author":"Rothman","year":"1999","journal-title":"Circulation."},{"key":"B127","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/sj.bjp.0703570","article-title":"5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension","volume":"131","author":"MacLean","year":"2000","journal-title":"Br J Pharmacol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"D34","DOI":"10.1016\/j.jacc.2013.10.029","article-title":"Updated clinical classification of pulmonary hypertension","volume":"62","author":"Simonneau","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"d8012","DOI":"10.1136\/bmj.d8012","article-title":"Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries","volume":"344","author":"Kieler","year":"2012","journal-title":"BMJ."},{"key":"B130","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1161\/01.RES.0000126847.27660.69","article-title":"Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension","volume":"94","author":"Marcos","year":"2004","journal-title":"Circ Res."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1183\/09031936.02.00081302","article-title":"Pathobiology of pulmonary arterial hypertension","volume":"20","author":"Eddahibi","year":"2002","journal-title":"Eur Respir J."},{"key":"B132","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1164\/rccm.200509-1365OC","article-title":"Genetic association of the serotonin transporter in pulmonary arterial hypertension","volume":"173","author":"Machado","year":"2006","journal-title":"Am J Respir Crit Care Med."},{"key":"B133","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1164\/rccm.200509-1361OC","article-title":"Serotonin transporter polymorphisms in familial and idiopathic pulmonary arterial hypertension","volume":"173","author":"Willers","year":"2006","journal-title":"Am J Respir Crit Care Med."},{"key":"B134","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0002-9343(99)80156-9","article-title":"Increased plasma serotonin in primary pulmonary hypertension","volume":"99","author":"Herv\u00e9","year":"1995","journal-title":"Am J Med."},{"key":"B135","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1161\/01.ATV.20.10.2233","article-title":"High plasma serotonin levels in primary pulmonary hypertension","volume":"20","author":"K\u00e9reveur","year":"2000","journal-title":"Arteriosclerosis Thrombosis Vasc Biol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3109\/14017431.2014.886335","article-title":"Venous plasma serotonin is not a proper biomarker for pulmonary arterial hypertension","volume":"48","author":"Zeinali","year":"2014","journal-title":"Scand Cardiovasc J."},{"key":"B137","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.pupt.2007.01.003","article-title":"Plasma serotonin levels are normal in pulmonary arterial hypertension","volume":"21","author":"Lederer","year":"2008","journal-title":"Pulm Pharmacol Ther."},{"key":"B138","doi-asserted-by":"publisher","first-page":"L810","DOI":"10.1152\/ajplung.00167.2020","article-title":"Protein biomarkers and risk scores in pulmonary arterial hypertension associated with ventricular septal defect: integration of multi-omics and validation","volume":"319","author":"Yuan","year":"2020","journal-title":"Am J Physiol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1165\/rcmb.2019-0015OC","article-title":"Comparison of human and experimental pulmonary veno-occlusive disease","volume":"63","author":"Manaud","year":"2020","journal-title":"Am J Respir Cell Mol Biol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3390\/ph14050394","article-title":"Role of osteopontin as a potential biomarker of pulmonary arterial hypertension in patients with systemic sclerosis and other connective tissue diseases (CTDs)","volume":"14","author":"Bellan","year":"2021","journal-title":"Pharmaceuticals."},{"key":"B141","doi-asserted-by":"publisher","first-page":"L1","DOI":"10.1152\/ajplung.00050.2012","article-title":"Osteopontin is an endogenous modulator of the constitutively activated phenotype of pulmonary adventitial fibroblasts in hypoxic pulmonary hypertension","volume":"303","author":"Anwar","year":"2012","journal-title":"Am J Physiol Lung Cell Mol Physiol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1172\/JCI12980","article-title":"Osteopontin as a means to cope with environmental insults: Regulation of inflammation, tissue remodeling, and cell survival","volume":"107","author":"Denhardt","year":"2001","journal-title":"J Clin Investig."},{"key":"B143","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1161\/ATVBAHA.116.307839","article-title":"Osteopontin, a key mediator expressed by senescent pulmonary vascular cells in pulmonary hypertension","volume":"36","author":"Saker","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1111\/resp.13557","article-title":"Osteopontin lung gene expression is a marker of disease severity in pulmonary arterial hypertension","volume":"24","author":"Mura","year":"2019","journal-title":"Respirology."},{"key":"B145","doi-asserted-by":"publisher","first-page":"621S","DOI":"10.1378\/chest.128.6_suppl.621S-a","article-title":"Osteopontin may be responsible for pulmonary vascular remodeling","volume":"128","author":"Hoshikawa","year":"2005","journal-title":"Chest."},{"key":"B146","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1378\/chest.10-1146","article-title":"Osteopontin in patients with idiopathic pulmonary hypertension","volume":"139","author":"Lorenzen","year":"2011","journal-title":"Chest."},{"key":"B147","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.ijcard.2011.12.108","article-title":"Osteopontin (OPN) improves risk stratification in pulmonary hypertension (PH)","volume":"155","author":"Rosenberg","year":"2012","journal-title":"Int J Cardiol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/j.1365-2362.2012.02671.x","article-title":"Osteopontin predicts adverse right ventricular remodelling and dysfunction in pulmonary hypertension","volume":"42","author":"Rosenberg","year":"2012","journal-title":"Eur J Clin Invest."},{"key":"B149","doi-asserted-by":"publisher","first-page":"7236","DOI":"10.1096\/fj.201802121RR","article-title":"Osteopontin plays important roles in pulmonary arterial hypertension induced by systemic-to-pulmonary shunt","volume":"33","author":"Meng","year":"2019","journal-title":"FASEB J."},{"key":"B150","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1055\/s-0039-1692174","article-title":"Potential involvement of osteopontin in inflammatory and fibrotic processes in pulmonary embolism and chronic thromboembolic pulmonary hypertension","volume":"119","author":"K\u00f6lmel","year":"2019","journal-title":"Thromb Haemost."},{"key":"B151","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1378\/chest.128.4.2355","article-title":"von Willebrand factor independently predicts long-term survival in patients with pulmonary arterial hypertension","volume":"128","author":"Kawut","year":"2005","journal-title":"Chest."},{"key":"B152","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1161\/01.CIR.102.20.2460","article-title":"Improvement of von Willebrand factor proteolysis after prostacyclin infusion in severe pulmonary arterial hypertension","volume":"102","author":"Veyradier","year":"2000","journal-title":"Circulation."},{"key":"B153","doi-asserted-by":"publisher","first-page":"204589402110415","DOI":"10.1177\/20458940211041500","article-title":"Plasma ADAMTS13 and von Willebrand factor in diagnosis and prediction of prognosis in pulmonary arterial hypertension","volume":"11","author":"Ahmed","year":"2021","journal-title":"Pulmonary Circul."},{"key":"B154","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1161\/01.CIR.96.9.2782","article-title":"Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension","volume":"96","author":"Friedman","year":"1997","journal-title":"Circulation."},{"key":"B155","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1378\/chest.114.5.1276","article-title":"Circulating von Willebrand factor antigen as a predictor of short-term prognosis in pulmonary hypertension","volume":"114","author":"Lopes","year":"1998","journal-title":"Chest."},{"key":"B156","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1183\/09031936.98.12061446","article-title":"Plasma coagulation profiles in patients with severe primary pulmonary hypertension","volume":"12","author":"Hoeper","year":"1998","journal-title":"Eur Respir J."},{"key":"B157","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/BF01747854","article-title":"Characterization of von Willebrand factor in primary pulmonary hypertension","volume":"14","author":"Collados","year":"1999","journal-title":"Heart Vessels."},{"key":"B158","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0002-9343(98)00138-7","article-title":"Abnormalities in circulating von Willebrand factor and survival in pulmonary hypertension","volume":"105","author":"Lopes","year":"1998","journal-title":"Am J Med."},{"key":"B159","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1513\/AnnalsATS.201508-543OC","article-title":"Prognostic significance of biomarkers in pulmonary arterial hypertension","volume":"13","author":"Al-Naamani","year":"2016","journal-title":"Ann Am Thorac Soc."},{"key":"B160","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1590\/S0100-879X2011007500149","article-title":"Plasma von Willebrand factor as a predictor of survival in pulmonary arterial hypertension associated with congenital heart disease","volume":"44","author":"Lopes","year":"2011","journal-title":"Brazil J Med Biol Res."},{"key":"B161","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S0002-8703(00)90038-3","article-title":"Endothelial cell dysfunction correlates differentially with survival in primary and secondary pulmonary hypertension","volume":"139","author":"Lopes","year":"2000","journal-title":"Am Heart J."},{"key":"B162","doi-asserted-by":"publisher","first-page":"e12106","DOI":"10.1371\/journal.pone.0012106","article-title":"Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury","volume":"5","author":"Pendergrass","year":"2010","journal-title":"PLoS ONE."},{"key":"B163","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1093\/rheumatology\/kes068","article-title":"Baseline vWF factor predicts the development of elevated pulmonary artery pressure in systemic sclerosis","volume":"51","author":"Barnes","year":"2012","journal-title":"Rheumatology."},{"key":"B164","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1136\/ard.2007.080424","article-title":"Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension","volume":"67","author":"Iannone","year":"2008","journal-title":"Ann Rheum Dis."},{"key":"B165","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1747-0803.2009.00297.x","article-title":"Patients with pulmonary hypertension related to congenital systemic-to-pulmonary shunts are characterized by inflammation involving endothelial cell activation and platelet-mediated inflammation","volume":"4","author":"Brun","year":"2009","journal-title":"Congenit Heart Dis."},{"key":"B166","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1183\/16000617.0009-2016","article-title":"Cell-derived microparticles and the lung","volume":"25","author":"Nieri","year":"2016","journal-title":"Eur Respir Rev."},{"key":"B167","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1161\/01.HYP.0000231507.00962.b5","article-title":"Circulating microparticles: a potential prognostic marker for atherosclerotic vascular disease","volume":"48","author":"Boulanger","year":"2006","journal-title":"Hypertension."},{"key":"B168","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1164\/rccm.200909-1347OC","article-title":"Circulating microparticles from pulmonary hypertensive rats induce endothelial dysfunction","volume":"182","author":"Tual-Chalot","year":"2010","journal-title":"Am J Respir Crit Care Med."},{"key":"B169","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1164\/rccm.200706-840OC","article-title":"Procoagulant membrane microparticles correlate with the severity of pulmonary arterial hypertension","volume":"177","author":"Bakouboula","year":"2008","journal-title":"Am J Respir Crit Care Med."},{"key":"B170","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1164\/rccm.200710-1458OC","article-title":"Circulating endothelial microparticle levels predict hemodynamic severity of pulmonary hypertension","volume":"177","author":"Amabile","year":"2008","journal-title":"Am J Respir Crit Care Med."},{"key":"B171","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.healun.2009.06.005","article-title":"Increased CD62e(+) endothelial microparticle levels predict poor outcome in pulmonary hypertension patients","volume":"28","author":"Amabile","year":"2009","journal-title":"J Heart Lung Transplant."},{"key":"B172","doi-asserted-by":"publisher","first-page":"e0156940","DOI":"10.1371\/journal.pone.0156940","article-title":"Flow cytometric quantification of peripheral blood cell \u03b2-adrenergic receptor density and urinary endothelial cell-derived microparticles in pulmonary arterial hypertension","volume":"11","author":"Rose","year":"2016","journal-title":"PLoS ONE."},{"key":"B173","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2045894019864357","article-title":"Enhanced circulating levels of CD3 cells-derived extracellular vesicles in different forms of pulmonary hypertension","volume":"9","author":"Kosanovic","year":"2019","journal-title":"Pulmonary Circul."},{"key":"B174","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.thromres.2020.07.030","article-title":"Increased levels of platelet-derived microparticles in pulmonary hypertension","volume":"195","author":"Ogawa","year":"2020","journal-title":"Thrombosis Res."},{"key":"B175","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.3390\/cells10071688","article-title":"Circulating cell biomarkers in pulmonary arterial hypertension: relationship with clinical heterogeneity and therapeutic response","volume":"10","author":"Tura-Ceide","year":"2021","journal-title":"Cells."},{"key":"B176","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/resp.13500","article-title":"Microparticles in systemic sclerosis: Potential pro-inflammatory mediators and pulmonary hypertension biomarkers","volume":"24","author":"Lammi","year":"2019","journal-title":"Respirology."},{"key":"B177","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3109\/1354750X.2014.910551","article-title":"Are endothelial microparticles early markers of pulmonary hypertension?","volume":"19","author":"Narin","year":"2014","journal-title":"Biomarkers."},{"key":"B178","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1177\/1358863X13499773","article-title":"Endothelial microparticles: sophisticated vesicles modulating vascular function","volume":"18","author":"Curtis","year":"2013","journal-title":"Vasc Med."},{"key":"B179","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1684\/ecn.2016.0386","article-title":"Pulmonary artery hypertension: pertinent vasomotorial cytokines","volume":"28","author":"Yuan","year":"2017","journal-title":"Eur Cytokine Netw."},{"key":"B180","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1093\/eurheartj\/ehq226","article-title":"Circulating angiopoietins in idiopathic pulmonary arterial hypertension","volume":"31","author":"K\u00fcmpers","year":"2010","journal-title":"Eur Heart J."},{"key":"B181","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.healun.2009.09.005","article-title":"Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial","volume":"29","author":"Hiremath","year":"2010","journal-title":"J Heart Lung Transplant."},{"key":"B182","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1002\/art.41665","article-title":"Association of lymphangiogenic factors with pulmonary arterial hypertension in systemic sclerosis","volume":"73","author":"Didriksen","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"B183","doi-asserted-by":"publisher","first-page":"e0165982","DOI":"10.1371\/journal.pone.0165982","article-title":"Circulating angiopoietin-1 is not a biomarker of disease severity or prognosis in pulmonary hypertension","volume":"11","author":"Richter","year":"2016","journal-title":"PLoS ONE."},{"key":"B184","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/path.953","article-title":"Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis","volume":"195","author":"Tuder","year":"2001","journal-title":"J Pathol."},{"key":"B185","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1046\/j.1440-1827.2000.01068.x","article-title":"Expression of vascular endothelial growth factor and its receptors correlates closely with formation of the plexiform lesion in human pulmonary hypertension","volume":"50","author":"Hirose","year":"2000","journal-title":"Pathol Int."},{"key":"B186","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1152\/japplphysiol.00083.2002","article-title":"Pulmonary hypertension in TNF-alpha-overexpressing mice is associated with decreased VEGF gene expression","volume":"93","author":"Fujita","year":"2002","journal-title":"J Appl Physiol."},{"key":"B187","doi-asserted-by":"publisher","first-page":"00037","DOI":"10.1183\/23120541.00037-2019","article-title":"Plasma receptor tyrosine kinase RET in pulmonary arterial hypertension diagnosis and differentiation","volume":"5","author":"S\u00e4leby","year":"2019","journal-title":"ERJ Open Res."},{"key":"B188","doi-asserted-by":"publisher","first-page":"369","DOI":"10.4103\/2045-8932.110445","article-title":"Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension","volume":"3","author":"Malhotra","year":"2013","journal-title":"Pulmonary Circul."},{"key":"B189","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/03009742.2017.1378714","article-title":"Angiogenic and inflammatory biomarkers for screening and follow-up in patients with pulmonary arterial hypertension","volume":"47","author":"Kylhammar","year":"2018","journal-title":"Scand J Rheumatol."},{"key":"B190","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1183\/13993003.00187-2015","article-title":"New potential diagnostic biomarkers for pulmonary hypertension","volume":"46","author":"Tiede","year":"2015","journal-title":"Eur Respir J."},{"key":"B191","doi-asserted-by":"publisher","first-page":"143428","DOI":"10.1155\/2012\/143428","article-title":"Circulating cytokines and growth factors in pediatric pulmonary hypertension","volume":"2012","author":"Duncan","year":"2012","journal-title":"Mediators Inflamm."},{"key":"B192","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s13075-015-0712-4","article-title":"Biomarkers of pulmonary hypertension in patients with scleroderma: a case-control study","volume":"17","author":"McMahan","year":"2015","journal-title":"Arthritis Res Ther."},{"key":"B193","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1183\/09031936.00174908","article-title":"Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension","volume":"34","author":"Selimovic","year":"2009","journal-title":"Eur Respir J."},{"key":"B194","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1471-2466-9-18","article-title":"Serum VEGF levels are related to the presence of pulmonary arterial hypertension in systemic sclerosis","volume":"9","author":"Papaioannou","year":"2009","journal-title":"BMC Pulm Med."},{"key":"B195","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s10456-008-9101-9","article-title":"Endoglin in angiogenesis and vascular diseases","volume":"11","author":"ten Dijke","year":"2008","journal-title":"Angiogenesis."},{"key":"B196","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s00296-008-0829-8","article-title":"Potential biomarkers for detecting pulmonary arterial hypertension in patients with systemic sclerosis","volume":"29","author":"Coral-Alvarado","year":"2009","journal-title":"Rheumatol Int."},{"key":"B197","doi-asserted-by":"publisher","first-page":"17937","DOI":"10.1074\/jbc.275.24.17937","article-title":"Bone morphogenetic protein-9","volume":"275","author":"Miller","year":"2000","journal-title":"J Biol Chem."},{"key":"B198","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1210\/endo.136.10.7664647","article-title":"Bone morphogenetic protein-9 binds to liver cells and stimulates proliferation","volume":"136","author":"Song","year":"1995","journal-title":"Endocrinology."},{"key":"B199","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/sj.leu.2401363","article-title":"Bone morphogenetic protein 9 is a potent synergistic factor for murine hemopoietic progenitor cell generation and colony formation in serum-free cultures","volume":"13","author":"Ploemacher","year":"1999","journal-title":"Leukemia."},{"key":"B200","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1038\/sj.gt.3302075","article-title":"Osteogenic potential of five different recombinant human bone morphogenetic protein adenoviral vectors in the rat","volume":"10","author":"Li","year":"2003","journal-title":"Gene Therapy."},{"key":"B201","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/jcp.10025","article-title":"BMP-2 and BMP-9 promotes chondrogenic differentiation of human multipotential mesenchymal cells and overcomes the inhibitory effect of IL-1","volume":"189","author":"Majumdar","year":"2001","journal-title":"J Cell Physiol."},{"key":"B202","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1182\/blood-2006-07-034124","article-title":"Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells","volume":"109","author":"David","year":"2007","journal-title":"Blood."},{"key":"B203","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1161\/CIRCRESAHA.107.165530","article-title":"Bone morphogenetic protein-9 is a circulating vascular quiescence factor","volume":"102","author":"David","year":"2008","journal-title":"Circulation Res."},{"key":"B204","doi-asserted-by":"publisher","first-page":"15794","DOI":"10.1074\/jbc.M109.002881","article-title":"Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells","volume":"284","author":"Upton","year":"2009","journal-title":"J Biol Chem."},{"key":"B205","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/79226","article-title":"Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension","volume":"26","author":"International PPH","year":"2000","journal-title":"Nat Genet."},{"key":"B206","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1086\/513903","article-title":"The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2","volume":"61","author":"Berg","year":"1997","journal-title":"Am J Hum Genet."},{"key":"B207","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1038\/s41467-018-03672-4","article-title":"Identification of rare sequence variation underlying heritable pulmonary arterial hypertension","volume":"9","author":"Gr\u00e4f","year":"2018","journal-title":"Nat Commun."},{"key":"B208","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12890-016-0183-7","article-title":"Novel homozygous BMP9 nonsense mutation causes pulmonary arterial hypertension: a case report","volume":"16","author":"Wang","year":"2016","journal-title":"BMC Pulm Med."},{"key":"B209","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1183\/13993003.01609-2018","article-title":"Germline BMP9 mutation causes idiopathic pulmonary arterial hypertension","volume":"53","author":"Wang","year":"2019","journal-title":"Eur Respir J."},{"key":"B210","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1183\/13993003.01371-2018","article-title":"Widening the landscape of heritable pulmonary hypertension mutations in paediatric and adult cases","volume":"53","author":"Eyries","year":"2019","journal-title":"Eur Respir J."},{"key":"B211","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1164\/rccm.201906-1141OC","article-title":"Characterization of GDF2 mutations and levels of BMP9 and BMP10 in pulmonary arterial hypertension","volume":"201","author":"Hodgson","year":"2020","journal-title":"Am J Respir Crit Care Med."},{"key":"B212","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.18632\/aging.102726","article-title":"Bone morphogenetic protein 9, and its genetic variants contribute to susceptibility of idiopathic pulmonary arterial hypertension","volume":"12","author":"Guo","year":"2020","journal-title":"Aging."},{"key":"B213","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1164\/rccm.201807-1236OC","article-title":"Bone morphogenetic protein 9 is a mechanistic biomarker of portopulmonary hypertension","volume":"199","author":"Nikolic","year":"2019","journal-title":"Am J Respir Crit Care Med."},{"key":"B214","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/nm.3877","article-title":"Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med."},{"key":"B215","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1161\/CIRCRESAHA.118.313356","article-title":"Selective BMP-9 inhibition partially protects against experimental pulmonary hypertension","volume":"124","author":"Tu","year":"2019","journal-title":"Circulation Res."},{"key":"B216","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4103\/1817-1737.58953","article-title":"Portopulmonary hypertension","volume":"5","author":"Saleemi","year":"2010","journal-title":"Ann Thorac Med."},{"key":"B217","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/ng.2653","article-title":"The genotype-tissue expression (GTEx) project","volume":"45","author":"GTEx","year":"2013","journal-title":"Nat Genet."},{"key":"B218","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0092-8674(00)81848-6","article-title":"Endostatin: an endogenous inhibitor of angiogenesis and tumor growth","volume":"88","author":"O'Reilly","year":"1997","journal-title":"Cell."},{"key":"B219","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1165\/rcmb.2019-0056OC","article-title":"Functional impact of human genetic variants of COL18A1\/endostatin on pulmonary endothelium","volume":"62","author":"Goyanes","year":"2020","journal-title":"Am J Respir Cell Mol Biol."},{"key":"B220","doi-asserted-by":"publisher","first-page":"L1002","DOI":"10.1152\/ajplung.00383.2014","article-title":"Compartment-specific expression of collagens and their processing enzymesin intrapulmonary arteries of IPAH patients","volume":"308","author":"Hoffmann","year":"2015","journal-title":"Am J Physiol Lung Cell Mol Physiol."},{"key":"B221","doi-asserted-by":"publisher","first-page":"00378","DOI":"10.1183\/23120541.00378-2021","article-title":"The angiostatic peptide endostatin enhances mortality risk prediction in pulmonary arterial hypertension","volume":"7","author":"Simpson","year":"2021","journal-title":"ERJ Open Res."},{"key":"B222","doi-asserted-by":"publisher","first-page":"e021409","DOI":"10.1161\/JAHA.120.021409","article-title":"Angiostatic peptide, endostatin, predicts severity in pediatric congenital heart disease-associated pulmonary hypertension","volume":"10","author":"Daly","year":"2021","journal-title":"J Am Heart Assoc."},{"key":"B223","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1164\/rccm.201409-1742OC","article-title":"Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension","volume":"191","author":"Damico","year":"2015","journal-title":"Am J Respir Crit Care Med."},{"key":"B224","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s13075-015-0756-5","article-title":"Associations between circulating endostatin levels and vascular organ damage in systemic sclerosis and mixed connective tissue disease: an observational study","volume":"17","author":"Reiseter","year":"2015","journal-title":"Arthritis Res Ther."},{"key":"B225","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1373\/clinchem.2008.108886","article-title":"The evolving role of C-reactive protein in atherothrombosis","volume":"55","author":"Devaraj","year":"2009","journal-title":"Clinical Chemistry."},{"key":"B226","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1136\/heartjnl-2014-305494","article-title":"C-reactive protein in adults with pulmonary arterial hypertension associated with congenital heart disease and its prognostic value","volume":"100","author":"Scognamiglio","year":"2014","journal-title":"Heart."},{"key":"B227","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1755-5922.2009.00103.x","article-title":"Atorvastatin decreases c-reactive protein-induced inflammatory response in pulmonary artery smooth muscle cells by inhibiting nuclear factor-\u03bab pathway","volume":"28","author":"Li","year":"2010","journal-title":"Cardiovasc Therap."},{"key":"B228","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.jacc.2008.12.038","article-title":"C-reactive protein. A new predictor of adverse outcome in pulmonary arterial hypertension","volume":"53","author":"Quarck","year":"2009","journal-title":"J Am Coll Cardiol."},{"key":"B229","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1755-5922.2009.00128.x","article-title":"Inflammatory signaling in pulmonary arterial hypertension: The controversial role of CRP, and the search for new therapies","volume":"28","author":"MacIocia","year":"2010","journal-title":"Cardiovasc Therap."},{"key":"B230","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1378\/chest.06-2243","article-title":"A nuclear factor-\u03baB inhibitor pyrrolidine dithiocarbamate ameliorates pulmonary hypertension in rats","volume":"132","author":"Sawada","year":"2007","journal-title":"Chest."},{"key":"B231","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0378-1119(99)00309-1","article-title":"Characterization of the rat, mouse, and human genes of growth\/differentiation factor-15\/macrophage inhibiting cytokine-1 (GDF-15\/MIC-1)","volume":"237","author":"B\u00f6ttner","year":"1999","journal-title":"Gene."},{"key":"B232","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2045894020962948","article-title":"Growth differentiation factor-15 levels in the blood around the pulmonary artery is associated with hospitalization for heart failure in patients with pulmonary arterial hypertension","volume":"10","author":"Chang","year":"2020","journal-title":"Pulmonary Circul."},{"key":"B233","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s00441-004-0986-3","article-title":"Involvement of growth differentiation factor-15\/macrophage inhibitory cytokine-1 (GDF-15\/MIC-1) in oxLDL-induced apoptosis of human macrophages in vitro and in arteriosclerotic lesions","volume":"318","author":"Schlittenhardt","year":"2004","journal-title":"Cell Tissue Res."},{"key":"B234","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1164\/rccm.200802-235OC","article-title":"Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension","volume":"178","author":"Nickel","year":"2008","journal-title":"Am J Respir Crit Care Med."},{"key":"B235","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1164\/rccm.200712-1786OC","article-title":"Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism","volume":"177","author":"Lankeit","year":"2008","journal-title":"Am J Respir Crit Care Med."},{"key":"B236","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jacc.2007.04.091","article-title":"Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure","volume":"50","author":"Kempf","year":"2007","journal-title":"J Am Coll Cardiol."},{"key":"B237","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1161\/CIRCULATIONAHA.106.650846","article-title":"Prognostic value of growth-differentiation factor-15 in patients with non\u2013ST-elevation acute coronary syndrome","volume":"115","author":"Wollert","year":"2007","journal-title":"Circulation."},{"key":"B238","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1465-9921-12-62","article-title":"GDF-15 is abundantly expressed in plexiform lesions in patients with pulmonary arterial hypertension and affects proliferation and apoptosis of pulmonary endothelial cells","volume":"12","author":"Nickel","year":"2011","journal-title":"Respir Res."},{"key":"B239","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1183\/09031936.99.13368299","article-title":"Hyperuricaemia in patients with right or left heart failure","volume":"13","author":"Hoeper","year":"1999","journal-title":"Eur Respir J."},{"key":"B240","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1164\/ajrccm.160.2.9812078","article-title":"Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension","volume":"160","author":"Nagaya","year":"1999","journal-title":"Am J Respir Crit Care Med."},{"key":"B241","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3724\/SP.J.1263.2011.11281","article-title":"Serum uric acid as an index of impaired renal function in congestive heart failure","volume":"9","author":"Leyva","year":"1997","journal-title":"J Geriatric Cardiol."},{"key":"B242","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.semnephrol.2004.09.010","article-title":"Uric acid and survival in chronic heart failure","volume":"21","author":"Doehner","year":"2004","journal-title":"Cardiol Rev."},{"key":"B243","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1053\/rmed.2003.1440","article-title":"Hyperuricemia as a prognostic factor in pulmonary arterial hypertension","volume":"97","author":"Bendayan","year":"2003","journal-title":"Respir Med."},{"key":"B244","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1183\/13993003.00332-2020","article-title":"Serum and pulmonary uric acid in pulmonary arterial hypertension","volume":"58","author":"Savale","year":"2021","journal-title":"Eur Respir J."},{"key":"B245","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1155\/2020\/7265487","article-title":"Novel molecular mechanisms of pulmonary hypertension: a search for biomarkers and novel drug targets-from bench to bed site","volume":"2020","author":"Gajecki","year":"2020","journal-title":"Oxidative Med Cell Long."},{"key":"B246","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1089\/jir.2008.0027","article-title":"Monocyte chemoattractant protein-1 (MCP-1): An overview","volume":"29","author":"Deshmane","year":"2009","journal-title":"J Interferon Cytokine Res."},{"key":"B247","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/j.1440-1843.2006.00821.x","article-title":"Increased plasma monocyte chemoattractant protein-1 level in idiopathic pulmonary arterial hypertension","volume":"11","author":"Itoh","year":"2006","journal-title":"Respirology."},{"key":"B248","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1164\/rccm.200610-1559OC","article-title":"Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension","volume":"176","author":"Sanchez","year":"2007","journal-title":"Am J Respir Crit Care Med."},{"key":"B249","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1253\/circj.68.227","article-title":"Epoprostenol therapy decreases elevated circulating levels of monocyte chemoattractant protein-1 in patients with primary pulmonary hypertension","volume":"68","author":"Hashimoto","year":"2004","journal-title":"Circul J."},{"key":"B250","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1164\/ajrccm.164.2.2006154","article-title":"Plasma monocyte chemoattractant protein-1 and pulmonary vascular resistance in chronic thromboembolic pulmonary hypertension","volume":"164","author":"Kimura","year":"2001","journal-title":"Am J Respir Crit Care Med."},{"key":"B251","doi-asserted-by":"publisher","first-page":"L784","DOI":"10.1152\/ajplung.00186.2018","article-title":"Galectin-3 is expressed in vascular smooth muscle cells and promotes pulmonary hypertension through changes in proliferation, apoptosis, and fibrosis","volume":"316","author":"Barman","year":"2019","journal-title":"Am J Physiol."},{"key":"B252","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1164\/ajrccm.151.5.7735624","article-title":"Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension","volume":"151","author":"Humbert","year":"1995","journal-title":"Am J Respir Crit Care Med."},{"key":"B253","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1159\/000495331","article-title":"Galectin-3- Mediated transdifferentiation of pulmonary artery endothelial cells contributes to hypoxic pulmonary vascular remodeling","volume":"51","author":"Zhang","year":"2018","journal-title":"Cell Physiol Biochem."},{"key":"B254","doi-asserted-by":"publisher","first-page":"116546","DOI":"10.1016\/j.lfs.2019.116546","article-title":"Galectin-3 aggravates pulmonary arterial hypertension via immunomodulation in congenital heart disease","volume":"232","author":"Shen","year":"2019","journal-title":"Life Sci."},{"key":"B255","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1136\/heartjnl-2015-308365","article-title":"Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension","volume":"102","author":"Calvier","year":"2016","journal-title":"Heart."},{"key":"B256","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s00380-015-0691-z","article-title":"Galectin-3 levels are associated with right ventricular functional and morphologic changes in pulmonary arterial hypertension","volume":"31","author":"Fenster","year":"2016","journal-title":"Heart Vessels."},{"key":"B257","doi-asserted-by":"publisher","first-page":"e109291","DOI":"10.1371\/journal.pone.0109291","article-title":"Systematic analysis of blood cell transcriptome in end-stage chronic respiratory diseases","volume":"9","author":"Chesn\u00e9","year":"2014","journal-title":"PLoS ONE."},{"key":"B258","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.hlc.2016.12.012","article-title":"Galectin-3 levels are elevated and predictive of mortality in pulmonary hypertension","volume":"26","author":"Mazurek","year":"2017","journal-title":"Heart Lung Circul."},{"key":"B259","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/diagnostics10110857","article-title":"Galectin-3 plasma levels are associated with risk profiles in pulmonary arterial hypertension","volume":"10","author":"Scelsi","year":"2020","journal-title":"Diagnostics."},{"key":"B260","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1093\/eurjhf\/hfq091","article-title":"Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure","volume":"12","author":"Shah","year":"2010","journal-title":"Eur J Heart Fail."},{"key":"B261","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1161\/CIRCULATIONAHA.109.933762","article-title":"Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension","volume":"122","author":"Soon","year":"2010","journal-title":"Circulation."},{"key":"B262","doi-asserted-by":"publisher","first-page":"e720305","DOI":"10.1155\/2010\/720305","article-title":"Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension","volume":"2010","author":"Furuya","year":"2010","journal-title":"Int J Rheumatol."},{"key":"B263","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1183\/13993003.01448-2015","article-title":"Role of interleukin-1 receptor 1\/MyD88 signalling in the development and progression of pulmonary hypertension","volume":"48","author":"Parpaleix","year":"2016","journal-title":"Eur Respir J."},{"key":"B264","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1465-9921-10-6","article-title":"Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice","volume":"10","author":"Savale","year":"2009","journal-title":"Respir Res."},{"key":"B265","doi-asserted-by":"publisher","first-page":"E2677","DOI":"10.1073\/pnas.1424774112","article-title":"Interleukin-6\/interleukin-21 signaling axis is critical in the pathogenesis of pulmonary arterial hypertension","volume":"112","author":"Hashimoto-Kataoka","year":"2015","journal-title":"Proc Natl Acad Sci USA."},{"key":"B266","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1165\/rcmb.2008-0109TR","article-title":"Isoprostanes and lung vascular pathology","volume":"39","author":"Janssen","year":"2008","journal-title":"Am J Respir Cell Mol Biol."},{"key":"B267","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1096\/fj.04-2330rev","article-title":"Isoprostanes: markers and mediators of oxidative stress","volume":"18","author":"Montuschi","year":"2004","journal-title":"FASEB J."},{"key":"B268","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1378\/chest.11-1267","article-title":"Independent association of urinary F2-Isoprostanes with survival in pulmonary arterial hypertension","volume":"142","author":"Cracowski","year":"2012","journal-title":"Chest."},{"key":"B269","doi-asserted-by":"publisher","first-page":"R1406","DOI":"10.1152\/ajpregu.1998.274.5.R1406","article-title":"A novel mechanism for vasoconstrictor action of 8-isoprostaglandin F(2\u03b1) on retinal vessels","volume":"274","author":"Lahaie","year":"1998","journal-title":"Am J Physiol."},{"key":"B270","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1378\/chest.12-0848","article-title":"F2 -Isoprostanes","volume":"142","author":"Dromparis","year":"2012","journal-title":"Chest."},{"key":"B271","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.freeradbiomed.2004.11.033","article-title":"Oxidant stress but not thromboxane decreases with epoprostenol therapy","volume":"38","author":"Robbins","year":"2005","journal-title":"Free Rad Biol Med."},{"key":"B272","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ijcard.2014.05.014","article-title":"Plasma 15-F2t-isoprostane in idiopathic pulmonary arterial hypertension","volume":"175","author":"Zhang","year":"2014","journal-title":"Int J Cardiol."},{"key":"B273","doi-asserted-by":"publisher","first-page":"72","DOI":"10.4103\/2045-8932.78107","article-title":"Oxidative injury is a common consequence of BMPR2 mutations","volume":"1","author":"Lane","year":"2011","journal-title":"Pulmonary Circul."},{"key":"B274","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/S0140-6736(98)05768-7","article-title":"Increased lipid peroxidation in patients with rhabdomyolysis","volume":"353","author":"Holt","year":"1999","journal-title":"Lancet."},{"key":"B275","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/0005-2760(85)90166-3","article-title":"Formation of 15-HETE as a major hydroxyeicosatetraenoic acid in the atherosclerotic vessel wall","volume":"834","author":"Henriksson","year":"1985","journal-title":"Biochim Biophys Acta."},{"key":"B276","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1161\/01.ATV.20.9.2100","article-title":"Overexpression of 15-lipoxygenase in vascular endothelium accelerates early atherosclerosis in LDL receptor-deficient mice","volume":"20","author":"Harats","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B277","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1086\/683695","article-title":"Proinflammatory high-density lipoprotein results from oxidized lipid mediators in the pathogenesis of both idiopathic and associated types of pulmonary arterial hypertension","volume":"5","author":"Ross","year":"2015","journal-title":"Pulmonary Circul."},{"key":"B278","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1086\/686311","article-title":"Plasma 12- and 15-hydroxyeicosanoids are predictors of survival in pulmonary arterial hypertension","volume":"6","author":"Al-Naamani","year":"2016","journal-title":"Pulmonary Circul."},{"key":"B279","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1164\/rccm.200301-147OC","article-title":"Oxidative stress in severe pulmonary hypertension","volume":"169","author":"Bowers","year":"2004","journal-title":"Am J Respir Crit Care Med."},{"key":"B280","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.plefa.2011.10.001","article-title":"Hypoxia promotes rabbit pulmonary artery smooth muscle cells proliferation through a 15-LOX-2 product 15(S)-hydroxyeicosatetraenoic acid","volume":"86","author":"Shan","year":"2012","journal-title":"Prostaglandins Leukot Essent Fatty Acids."},{"key":"B281","doi-asserted-by":"publisher","first-page":"L367","DOI":"10.1152\/ajplung.00114.2005","article-title":"Role of 12-lipoxygenase in hypoxia-induced rat pulmonary artery smooth muscle cell proliferation","volume":"290","author":"Preston","year":"2006","journal-title":"Am J Physiol Lung Cell Mol Physiol."},{"key":"B282","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1161\/HYPERTENSIONAHA.111.171561","article-title":"Key role of 15-lipoxygenase\/15-hydroxyeicosatetraenoic acid in pulmonary vascular remodeling and vascular angiogenesis associated with hypoxic pulmonary hypertension","volume":"58","author":"Ma","year":"2011","journal-title":"Hypertension."},{"key":"B283","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/jcp.24443","article-title":"15-LO\/15-HETE mediated vascular adventitia fibrosis via p38 MAPK-dependent TGF-\u03b2","volume":"229","author":"Zhang","year":"2014","journal-title":"J Cell Physiol."},{"key":"B284","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1161\/HYPERTENSIONAHA.120.14697","article-title":"Oral 15-hydroxyeicosatetraenoic acid induces pulmonary hypertension in mice by triggering T cell-dependent endothelial cell apoptosis","volume":"76","author":"Ruffenach","year":"2020","journal-title":"Hypertension."},{"key":"B285","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1194\/jlr.M033555","article-title":"A novel approach to oral apoA-I mimetic therapy","volume":"54","author":"Chattopadhyay","year":"2013","journal-title":"J Lipid Res."},{"key":"B286","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1194\/jlr.M076554","article-title":"Transgenic tomatoes expressing the 6F peptide and ezetimibe prevent diet-induced increases of IFN-\u03b2 and cholesterol 25-hydroxylase in jejunum","volume":"58","author":"Mukherjee","year":"2017","journal-title":"J Lipid Res."},{"key":"B287","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/PL00000776","article-title":"The CD40 \/ CD154 receptor \/ ligand dyad","volume":"58","author":"Libby","year":"2001","journal-title":"Cell Mol Life Sci."},{"key":"B288","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1159\/000430130","article-title":"Interruption of CD40 pathway improves efficacy of transplanted endothelial progenitor cells in monocrotaline induced pulmonary arterial hypertension","volume":"36","author":"Pan","year":"2015","journal-title":"Cell Physiol Biochem."},{"key":"B289","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1161\/01.CIR.0000139859.68513.FC","article-title":"Soluble CD40 ligand in pulmonary arterial hypertension: Possible pathogenic role of the interaction between platelets and endothelial cells","volume":"110","author":"Dam\u00e5s","year":"2004","journal-title":"Circulation."},{"key":"B290","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s00726-010-0752-7","article-title":"Tryptophan metabolism, from nutrition to potential therapeutic applications","volume":"41","author":"le Floc'h","year":"2011","journal-title":"Amino Acids."},{"key":"B291","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jacc.2015.10.072","article-title":"Metabolic profiling of right ventricular-pulmonary vascular function reveals circulating biomarkers of pulmonary hypertension","volume":"67","author":"Lewis","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"B292","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1021\/acsomega.1c05895","article-title":"Metabolic reprogramming of the right ventricle and pulmonary arteries in a flow-associated pulmonary arterial hypertension rat model","volume":"7","author":"Liu","year":"2022","journal-title":"ACS Omega."},{"key":"B293","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1152\/ajplung.00517.2016","article-title":"Importance of kynurenine in pulmonary hypertension","volume":"313","author":"Nagy","year":"2017","journal-title":"Am J Physiol Lung Cell Mol Physiol."},{"key":"B294","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1136\/heartjnl-2015-308581","article-title":"Activity of the kynurenine pathway and its interplay with immunity in patients with pulmonary arterial hypertension","volume":"102","author":"Jasiewicz","year":"2016","journal-title":"Heart."},{"key":"B295","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1161\/CIRCULATIONAHA.116.024602","article-title":"Plasma metabolomics implicates modified transfer RNAs and altered bioenergetics in the outcomes of pulmonary arterial hypertension","volume":"135","author":"Rhodes","year":"2017","journal-title":"Circulation."},{"key":"B296","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2174\/157340310790231662","article-title":"Ghrelin and cardiovascular diseases","volume":"6","author":"Zhang","year":"2010","journal-title":"Curr Cardiol Rev."},{"key":"B297","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/sj.bjp.0704815","article-title":"Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1","volume":"136","author":"Wiley","year":"2002","journal-title":"Br J Pharmacol."},{"key":"B298","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.molmet.2015.03.005","article-title":"Ghrelin","volume":"4","author":"M\u00fcller","year":"2015","journal-title":"Mol Metab."},{"key":"B299","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1159\/000348368","article-title":"Ghrelin and its relation with N-terminal brain natriuretic peptide, endothelin-1 and nitric oxide in patients with idiopathic pulmonary hypertension","volume":"124","author":"Yang","year":"2013","journal-title":"Cardiology."},{"key":"B300","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1007\/s00246-015-1178-5","article-title":"Plasma levels of acylated ghrelin in children with pulmonary hypertension associated with congenital heart disease","volume":"36","author":"Li","year":"2015","journal-title":"Pediatr Cardiol."},{"key":"B301","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.3760\/cma.j.issn.0366-6999.20123353","article-title":"Circulating ghrelin was negatively correlated with pulmonary arterial pressure in atrial septal defect patients","volume":"126","author":"Li","year":"2013","journal-title":"Chin Med J."},{"key":"B302","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1210\/en.2007-0833","article-title":"Exogenous ghrelin attenuates the progression of chronic hypoxia-induced pulmonary hypertension in conscious rats","volume":"149","author":"Schwenke","year":"2008","journal-title":"Endocrinology."},{"key":"B303","doi-asserted-by":"publisher","first-page":"H2885","DOI":"10.1152\/ajpheart.01122.2003","article-title":"Endogenous production of ghrelin and beneficial effects of its exogenous administration in monocrotaline-induced pulmonary hypertension","volume":"287","author":"Henriques-Coelho","year":"2004","journal-title":"Am J Physiol Heart Circul Physiol."},{"key":"B304","doi-asserted-by":"publisher","first-page":"54742","DOI":"10.1074\/jbc.M409140200","article-title":"Role of Pim-1 in smooth muscle cell proliferation","volume":"279","author":"Katakami","year":"2004","journal-title":"J Biol Chem."},{"key":"B305","first-page":"2486","article-title":"The human PIM-1 gene product is a protein serine kinase","volume":"51","author":"Padma","year":"1991","journal-title":"Cancer Res."},{"key":"B306","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1161\/CIRCULATIONAHA.110.963314","article-title":"Signal transducers and activators of transcription-3\/Pim1 Axis plays a critical role in the pathogenesis of human pulmonary arterial hypertension","volume":"123","author":"Paulin","year":"2011","journal-title":"Circulation."},{"key":"B307","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1084\/jem.20101812","article-title":"Role for miR-204 in human pulmonary arterial hypertension","volume":"208","author":"Courboulin","year":"2011","journal-title":"J Experi Med."},{"key":"B308","doi-asserted-by":"publisher","first-page":"11418","DOI":"10.1073\/pnas.0610467104","article-title":"The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted","volume":"104","author":"Bonnet","year":"2007","journal-title":"Proc Natl Acad Sci USA."},{"key":"B309","doi-asserted-by":"publisher","first-page":"74","DOI":"10.4103\/2045-8932.109917","article-title":"Pim-1: A new biomarker in pulmonary arterial hypertension","volume":"3","author":"Renard","year":"2013","journal-title":"Pulmonary Circul."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.924873\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T07:32:07Z","timestamp":1657783927000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.924873\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,14]]},"references-count":309,"alternative-id":["10.3389\/fcvm.2022.924873"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.924873","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,14]]},"article-number":"924873"}}